TABLE 3.

Mean Growth Rate in Children Aged 12–47 Months With Persistent/Recurrent Wheeze After Treatment With FP or SCG for 52 Weeks

Growth Rate (mm/y)FPSCGGrowth Rate Statistics
Mixed-model analysis
Height and length(n = 471)(n = 153)Diff: −2.4 mm/y
84.0 ± 1.186.4 ± 1.8CI: −6.6 to 1.8
P = .259
Height only(n = 346)(n = 107)Diff: −2.4 mm/y
78.9 ± 1.181.3 ± 1.9CI: −6.7 to 2.0
P = .288
Length only(n = 113)(n = 44)Diff: −0.3 mm/y
100.8 ± 2.2101.1 ± 3.4CI: −8.1 to 7.5
P = .936
Height and length, first 3 mo(n = 471)(n = 153)Diff: −5.1 mm/y
85.8 ± 2.490.9 ± 4.2CI: −14.5 to 4.3
P = .289
Regression slopes(n = 466)(n = 152)Diff: −0.0
Height and length85.3 ± 1.585.3 ± 2.4CI: −5.2 to 5.2
P = 0.993
Growth rate by subgroup*
 Steroid history
  Steroid takers(n = 167)(n = 60)Diff: −3.5 mm/y
  83.7 ± 1.887.2 ± 3.0CI: −10.4 to 3.4
  Steroid naïve(n = 304)(n = 93)Diff: −1.6 mm/y
84.2 ± 1.385.8 ± 2.4CI: −7.0 to 3.7
 Age
  <2 y(n = 123)(n = 37)Diff: −5.4 mm/y
101.4 ± 1.8106.7 ± 3.3CI: −12.7 to 2.0
  ≥2 y(n = 348)(n = 116)Diff: −2.2 mm/y
77.8 ± 1.180.0 ± 1.9CI: −6.4 to 2.0
 Gender
  Male(n = 300)(n = 110)Diff: −1.3 mm/y
83.1 ± 1.384.3 ± 2.1CI: −6.2 to 3.7
  Female(n = 171)(n = 43)Diff: −6.6 mm/y
85.7 ± 1.892.3 ± 3.7CI: −14.7 to 1.4
  • * None of the treatment-by-time interactions with these covariates was significant.